{
  "denotations": [
    {
      "id": "T1",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 40,
        "end": 60
      }
    },
    {
      "id": "T2",
      "obj": "Chemical",
      "span": {
        "begin": 170,
        "end": 196
      }
    },
    {
      "id": "T3",
      "obj": "Chemical",
      "span": {
        "begin": 201,
        "end": 210
      }
    },
    {
      "id": "T4",
      "obj": "Disease",
      "span": {
        "begin": 303,
        "end": 306
      }
    },
    {
      "id": "T6",
      "obj": "Disease",
      "span": {
        "begin": 281,
        "end": 300
      }
    },
    {
      "id": "T7",
      "obj": "Chemical",
      "span": {
        "begin": 170,
        "end": 210
      }
    },
    {
      "id": "T9",
      "obj": "Disease",
      "span": {
        "begin": 281,
        "end": 345
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "27525598_2",
  "text": "BACKGROUND : A polymorphism upstream of interleukin (IL)-28B was recently identified to be associated with a 2-fold difference in sustained virologic response ( SVR ) to pegylated interferon-alpha and ribavirin therapy in a large cohort of treatment-naive , adherent patients with chronic hepatitis C ( CHC ) virus genotype 1 ( HCV-1 ) infection ."
}
